Introduction
Arachidonic acid mainly serves as a precurser for the highly active lipid metabolites, eicosanoids. The metabolism of arachidonic acid is either catalysed via the cyclooxygenase (COX) pathway leading to the production of prostaglandins and thromboxanes, or the lipoxygenase (LO) pathway leading to the production of leukotrienes, hydroxyeicosatetraenoic acids and lipoxins. Earlier reports have implied that compounds that inhibit enzymes involved in the metabolism of arachidonic acid also affect cell proliferation and cell death in many normal as well as tumour cell types, and thus have a potential role as antitumour drugs (Murakami et al., 1997; Hennig et al., 2004; Mann and DuBois, 2004) . For example, inhibition of 5-lipoxygenase (5-LO) by MK-886 completely blocks 5-hydroxyeicosatetraenoic acid (5-HETE) production and induces apoptosis in both hormone-responsive and hormonenon-responsive (PC3) human prostate cancer cells, similar results are also found in other cell types (Ghosh and Myers, 1998; Pachernik et al., 2002; Wu et al., 2003) .
Cysteinyl leukotrienes (CysLTs), derived from arachidonic acid via the 5-LO pathway, have a number of pathophysiologic activities (Claesson and Dahlen, 1999) . Leukotriene D 4 (LTD 4 ) is the most potent of the three CysLTs (LTC 4 , LTD 4 and LTE 4 ) and its effects are mediated through either one of two G-protein-coupled receptors, CysLT 1 or CysLT 2 (Lynch et al., 1999; Heise et al., 2000; Funk, 2001) . The CysLT 1 receptor (CysLT 1 R) can activate different intracellular pathways, and thus simultaneously regulate various cellular functions. We have recently shown that in nontumour intestinal epithelial cells, LTD 4 induces a proliferative and a cell survival response via separate signalling pathways (Paruchuri et al., 2002; Paruchuri and Sjo¨lander, 2003) . In accordance with a role for LTD 4 in cell survival, it causes an upregulation of factors such as COX-2, b-catenin and the cell survival protein Bcl-2 (Ö hd et al., 2000) . Such effects indicate that this inflammatory mediator may contribute to increased survival of intestinal epithelial cells during chronic inflammatory conditions, some of which are known to be associated with an increased risk of developing cancer. A report from our laboratory proposes that signalling through the CysLT 1 R also facilitates survival of colon cancer cells and that its expression and nuclear localization is increased in colorectal adenocarcinomas (Ö hd et al., 2000 Nielsen et al., 2005) . The above findings highlight the potential use of both epithelial 5-LO (Ö hd et al., 2003) and the CysLT 1 R (Paruchuri and Sjo¨lander, 2003) as accessible pharmacological targets for the treatment of inflammatory intestinal diseases (Brink et al., 2003) .
To study the functional effects of endogenously released CysLTs we chose the non-tumour cell line, Int 407. These cells were pretreated or not with the CysLT 1 R antagonist MK571, stained with propidium iodide, and analysed by flow cytometry. Treatment with the MK571 resulted in an attenuation of the G 0 /G 1 phase, over 50% reduction of the S þ G 2 /M phase, and a significant fivefold buildup of the sub-G 0 /G 1 phase (Figure 1a) . Similar results were obtained with another antagonist ZM198,615 (data not shown). These results suggested that the CysLT 1 R antagonists reduce proliferation and cause an increase in cell death/apoptosis in intestinal epithelial, Int 407, cells.
Thymidine incorporation and cell counting analysis confirmed the effect of the CysLT 1 R antagonists on intestinal cell proliferation. Cells were treated with varying concentrations of antagonist as indicated, and the incorporation of thymidine into the cells was measured. Both MK571 and ZM198,615 caused a concentration-dependent inhibition (84 and 72% at 50 mM) of proliferation as indicated by reduced incorporation of thymidine (Figure 1b) . We also counted the number of viable cells by a Trypan blue exclusion assay in cells incubated in the presence of either MK571 or ZM198,615. Incubation with increasing concentrations of MK571 led to a concomitant decrease in cell number, 5, 28, 56, 66 and 82% (Figure 1c) . We also compared the total number of cells following incubation with either the MK571 or the ZM198,615 antagonist (25 mM) to DMSO-treated control cells. We found that both treatments resulted in substantially reduced cell number, 66 and 69%, respectively, compared to the control cells ( Figure 1d ).
In Trypan blue exclusion experiments, reduced viability was evident in cells treated with the CysLT 1 R antagonists MK571 and ZM198,615 compared to untreated control cells. Treatment of cells with MK571, induced a fourfold enhancement in cell death at a concentration of 20 mM, and a sixfold increase in cell death at a concentration of 50 mM (Figure 2a , left panel). Both antagonists caused a similar increase in the rate of cell death (Figure 2a, right panel) .
In order to distinguish between apoptosis and necrosis, we further examined the cells, following antagonist treatment, by Hoechst 33342 staining. Hoechst 33342 staining of Int 407 cells treated with MK571 or ZM198,615 for 18 h revealed condensed and fragmented nuclear DNA, indicating that apoptosis was responsible for the cell death observed in the antagonisttreated cells. Figure 2b shows typical micrographs of untreated control cells (left panel) and MK571-treated cells (50 mM, right panel) stained with Hoechst 33342. Incubation with increasing concentrations of MK571 (10, 25 and 50 mM) led to a concomitant increase (8, 20 and 45%) in the number of condensed nuclei (Figure 2c , left panel). We compared the degree of apoptosis induced by the MK571 and ZM198,615 antagonists at 25 mM, and found that both treatments essentially gave similar responses at the same concentration (Figure 2c , right panel).
Our finding that CysLT 1 R antagonists induce apoptosis in intestinal epithelial cells was confirmed in another non-tumour intestinal cell line, IEC-6. As seen in Figure 3a , we also found a robust expression of CysLT 1 R in IEC-6 cells. Similar to the effects of CysLT 1 R antagonists in Int 407 cells, we found that these antagonists caused cell shrinkage, rounding up and cell detachment (Figure 3b ). We could again confirm this antagonist-induced cell death as apoptosis by increased caspase-3 activity and fragmentation of PARP in IEC-6 cells, as well as in Int 407 cells (Figure 3c ). 3 H]thymidine (0.5 mCi/well) was added to the cells during this incubation to enable determination of proliferation (Paruchuri and Sjo¨lander, 2003) . The cells were fixed and lysed immediately after the incubations. The lysates were then mixed with scintillation liquid and their radioactive contents determined in an LKB Wallace 1209 Rack Beta counter. (c and d) The cells were incubated for 18 h in the absence or presence of the indicated antagonist, after which the number of viable cells was counted in the presence of 0.2% Trypan blue. The data in panels b-d are given as mean7s.e. of at least three separate experiments. The statistical significances between control cells and antagonist-treated cells were evaluated using the unpaired Student's t-test, *Po0.05, **Po0.01 and ***Po0.001.
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These results clearly demonstrate the induction of apoptosis in two different non-tumour intestinal cell lines, by antagonism of the endogenous CysLT 1 R. These data suggest that an endogenous production of CysLT ligands was responsible for CysLT 1 R activation.
We examined the endogenous synthesis and release of CysLTs from both Int 407 and IEC-6, as well as two tumour intestinal cell lines, Caco-2 and SW480. Significant endogenous production and release of CysLTs was observed in all four cell lines examined (Table 1) . We also demonstrated that the release of CysLTs was enhanced by treatment with the calcium ionophore A23187 in three of the four cell lines (Table 1) .
To investigate if the blocking of CysLT 1 Rs would also affect proliferation and cell death in cancer cell lines, we chose two tumour cell lines, Caco-2 and SW480, that we have previously used in our studies of CysLT 1 R signalling and that exhibit an endogenous production of CysLTs (Table 1) . Flow cytometric analysis revealed that antagonist treatment did not significantly alter the sub-G 0 /G 1 phase (Figure 4a ). However, we noticed that the proliferation rate, as visualized by the S þ G 2 /M or ZM198,615 (50 mM) for 18 h under serum-free conditions and (b) cell morphology was visualized using a Nikon phase-contrast microscope and a Nikon F-300 camera at Â 10 magnification. Each phase-contrast micrograph shown is representative of at least three separate experiments. (c) The cells were subsequently lysed, the proteins separated by SDS-PAGE (10%) and immunoblotted with either an anti-caspase-3 (1:1000) or an anti-PARP (1:500) antibody. In the upper panels, both the proform (32 kDa) and the cleaved active form (17 kDa) of caspase-3 are seen, and in the lower panels, both the proform (116 kDa) and the cleaved form (85 kDa) of PARP are visible. The blots shown are representative of at least three separate experiments. The cells were grown for 5 days after which they were transferred to serum-free medium and incubated in the absence or presence of 5 mM ionophore A23187 for 30 min. The serum-free media were then collected and LTs were separated by solid-phase extraction. CysLTs from the samples were measured using a cysteinyl leukotriene EIA kit from Cayman. Data are given as means7s.e. from five separate experiments. Abbreviations: LT, leukotriene; cysteinyl leukotriene, CysLTs.
Autocrine CysLT 1 receptor signalling in intestinal cells S Paruchuri et al phase, was lowered (7-12%) by both of the CysLT 1 R antagonists (Figure 4a ). There was also a corresponding increase in the resting phase, or the G 0 /G 1 phase, suggesting a possible cell cycle arrest. We performed thymidine incorporation experiments to validate these results. Interestingly, both cell lines showed a significant attenuation in thymidine incorporation upon treatment with either antagonist (Figure 4b ). The effects on Int 407 are included for comparison. We also analysed how the number of cells was affected upon treatment with the antagonists. After 18 h, no significant reduction in cell number was detected; however, 36 h after treatment with the antagonists, the cell number was reduced significantly in Caco-2 cells and SW480 cells, with MK571 and ZM198,615, respectively (Figure 4b ). Despite the fact that both Caco-2 and SW480 cells express CysLT 1 R (Figure 4c) , none of the CysLT 1 R antagonists induced cell death in these tumour cell lines (Figure 4d ). To confirm this observation, we performed the same experiments with two other intestinal tumour cell lines, HCT-116 and HT-29, that also express CysLT 1 Rs (Figure 4c ). Again we found no effects of CysLT 1 R antagonists on HCT-116 or HT-29 cell death (Figure 4d ). The fact that the CysLT 1 R antagonistinduced cell death in non-tumour intestinal cells could be ascribed to apoptosis made us test the effect of CysLT 1 R antagonists on intestinal tumour cell apoptosis. In accordance with the above results, neither MK571 nor ZM198,615 induced activation of caspase-3 and cleavage of PARP in the tumour cell lines Caco-2, SW480, HCT-116 or HT-29 (Figure 4e ). We hypothesized that the inability of CysLT 1 R antagonists to induce cell death in tumour cells as in non-tumour cells could be related to our observation that there exists a fraction of CysLT 1 Rs that are localized in the nuclei of tumour intestinal cells (Nielsen et al., 2005) .
The nuclear CysLT 1 Rs in tumour cells are not accessible to CysLT 1 R antagonists added to the outside of the cells. Consequently, the above results could readily be explained if these nuclear CysLT 1 R maintain cell survival signalling. We attempted to indirectly inhibit this population of CysLT 1 Rs by inhibiting the formation of CysLTs in all cellular compartments. To achieve this, we incubated the intestinal cancer cells with the FLAP inhibitor MK-886, a known inhibitor of 5-LO activity. As shown in Figure 5a , inhibition of 5-LO activity caused significant cell shrinkage, rounding up, and detachment of all tumour cells (Caco-2, SW480, HCT-116 and HT-29). We could confirm this antagonist-induced cell death as apoptosis by increased caspase-3 activity and fragmentation of PARP (Figure 5b ). These data suggest that inhibition of endogenous CysLTs production by 5-LO inhibition, and thus impaired CysLT 1 R signalling throughout the cell, also causes an apoptotic response in tumour intestinal cells.
In the present study, we found that the intestinal epithelial cell lines Int 407, IEC-6, Caco-2 and SW480 all exhibit a significant expression of CysLT 1 R and a basal production and release of CysLTs. Production of CysLTs by Int 407 cells has previously only been documented after provocation of the cells with Salmonella typhimurium (Pace et al., 1993) . Analogous with the basal activity of COX-1 in many cell types, including intestinal epithelial cells (Mann and DuBois, 2004) , the present finding demonstrates similar basal activity of 5-LO in these cells.
Our findings led to the suspicion that this endogenous production of CysLTs could be part of an autocrine and/or paracrine activation of CysLT 1 Rs, and subsequently also of functional importance. Here, we explored these possibilities by the use of structurally different CysLT 1 R antagonists. As our research is presently focused on exploring a possible role for CysLT 1 Rs in intestinal cancer development, we were primarily interested in investigating how an endogenous basal production of LTD 4 might affect intestinal cell proliferation and survival. Morphological analysis revealed that all CysLT 1 R antagonists induced cell death in the non-tumour intestinal epithelial cell lines Int 407 and IEC-6. This cell death was identified as apoptotic cell death. Although an increased rate of apoptosis could well explain our observation of a significant decrease in cell number following incubation with CysLT 1 R antagonists, this reduction could equally well reflect a reduction in cell proliferation. Thymidine incorporation data clearly revealed that these CysLT 1 R antagonists also lowered the proliferation rate of intestinal cells. To address this, we analysed the cell cycle progression of MK571-treated intestinal cells by flow cytometry, an approach that allows a concurrent analysis of apoptosis and proliferation. We observed a reduction in the G 0 /G 1 and S þ G 2 /M phases, and a fivefold increase in the sub-G 0 /G 1 phase, indicating that there is a simultaneous increase of apoptosis and reduction in proliferation when non-tumour intestinal cells are incubated with a CysLT 1 R antagonist.
We have previously reported that addition of exogenous LTD 4 reduced the apoptotic effect induced by the COX-2 inhibitor NS398, and reduced the generation of tBid (Wikstro¨m et al., 2003) . Based on these results, we propose that LTD 4 , via CysLT 1 Rs, could potentially participate in coupling chronic inflammatory disease to the development of intestinal cancer. Recently, we obtained additional support for a role of LTD 4 and the CysLT 1 R in colon cancer by the finding that this receptor is highly expressed in colorectal adenocarcinoma, and that its level of expression negatively correlates with patient survival (Ö hd et al., 2003) . In pursuit of a better understanding of the functional roles of endogenous activation of CysLT 1 Rs, we also tested the effect of CysLT 1 R antagonists on four different colon cancer cell lines, Caco-2, SW480, HCT-116 and HT-29. In contrast to our results obtained with non-tumour intestinal cell lines, treatment of colon tumour cell lines with CysLT 1 R antagonists for as long as 18 h did not induce any cell death. However, interestingly enough, the proliferation rate of such cancer cell lines was significantly reduced in the presence of a CysLT 1 R antagonist. These results lend further support to the idea that CysLT 1 R signalling regulates proliferation and survival via distinct intracellular signalling pathways in intestinal epithelial cells (Paruchuri et al., 2002; Paruchuri and Sjo¨lander, 2003) . In addition, the results also reveal that in colon cancer cell lines, that exhibit a nuclear localization of CysLT 1 R (Nielsen et al., 2005) , blockade of cell surface CysLT 1 Rs will impair proliferation signalling, but not cell survival signalling. However, an apoptotic response could be observed in the presence of the cell-permeable 5-LO inhibitor that impairs the endogenous production of CysLTs and thus indirectly also CysLT 1 R signalling throughout the cell. These data suggest that nuclearlocalized CysLT 1 Rs in intestinal cancer cells have an essential role in CysLT survival signalling.
In a related investigation, it has been shown that inhibition of 5-LO leads to apoptosis in prostate PC3 cancer cells (Ghosh and Myers, 1998) . The investigators were able to reverse this effect by addition of exogenous 5-HETE. Furthermore, mice deficient in either g-glutamyl leukotrienase or g-glutamyl transpeptidase, the two enzymes capable of cleaving LTC 4 to LTD 4 , developed normally and were fertile (Shi et al., 2001; Maekawa et al., 2002) . However, mice deficient in both g-glutamyl leukotrienase and g-glutamyl transpeptidase failed to thrive and around 70% had died already before 4 weeks of the age. This in vivo effect could possibly be related to impaired survival signalling by LTD 4 . In addition, Lee et al. (2000) have demonstrated the existence of an adhesioninduced autocrine CysLTs pathway that signals survival in eosinophils.
In summary, we have previously shown that the presence of exogenous LTD 4 , for example provided by an inflammatory reaction, signals increased survival and proliferation in intestinal epithelial cells. Here, we make an important expansion of this concept by our novel finding of constitutive autocrine and/or paracrine CysLT 1 R activation in intestinal cells. In non-tumour intestinal cell lines, such receptor activation at the plasma membrane initiates signalling mechanisms that promote both survival and proliferation, whereas in tumour cells, the presence of nuclear CysLT 1 Rs, not affected by receptor antagonists, appears to be an essential source of survival signalling.
